Supporting Information

Lagace et al. 10.1073/pnas.0810137105




Fig. S1. Validation of a Cdk5 Ab for IHC. (A) Immunoblot of either striatal brain extract (S) or recombinant Cdk5 protein (C) with either Cdk5 monoclonal (1H3) or commercial Ab (Cell Signaling). (B) Immunofluorescent detection of Cdk5+ cells using the 1H3 antibody in cells overexpressing (Superfectamine, Qiagen) control (CMV) or Cdk5 (cdk5) plasmids. Immunofluorescent staining in the absence (C) or presence (D–F) of 1H3 anti-Cdk5 Ab illustrating Cdk5 expressing cells in the granule and pyramidal cell layers of hippocampus (D and E), as well as in the cortex (E) and Purkinje cells of cerebellum (F).